Effectiveness of the Lilly Connected Care Program in Improving Glycemic Management Among Patients With Type 2 Diabetes in China: Retrospective Real-world Study

作者全名："Su, Benli; Chen, Yu; Shen, Xingping; Guo, Jianchao; Ding, Yuchen; Ma, Xiao; Yang, Yuxin; Liu, Dongfang"

作者地址："[Su, Benli] Dalian Med Univ, Dept Endocrinol, Hosp 2, Dalian, Peoples R China; [Chen, Yu; Guo, Jianchao] Tianjin Med Univ, Dept Endocrinol, Hosp 2, Tianjin, Peoples R China; [Shen, Xingping] Xiamen Univ, Zhongshan Hosp, Sch Med, Dept Endocrinol, Xiamen, Peoples R China; [Ding, Yuchen; Ma, Xiao; Yang, Yuxin] Lilly Suzhou Pharmaceut Co Ltd, Shanghai, Peoples R China; [Liu, Dongfang] Chongqing Med Univ, Dept Endocrinol, Affiliated Hosp 2, Linjiang Rd 76, Chongqing 400010, Peoples R China"

通信作者："Liu, DF (通讯作者)，Chongqing Med Univ, Dept Endocrinol, Affiliated Hosp 2, Linjiang Rd 76, Chongqing 400010, Peoples R China."

来源：JOURNAL OF MEDICAL INTERNET RESEARCH

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001006078900001

JCR分区：Q1

影响因子：5.8

年份：2023

卷号：25

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：type 2 diabetes mellitus; T2DM; diabetes management; Lilly Connected Care Program; LCCP; hemoglobin A1c; real-word study

摘要："Background: Type 2 diabetes mellitus (T2DM) is a worldwide public health concern. Mobile health management platforms could be a potential way to achieve effective glycemic control. Objective: This study aimed to evaluate the real-world effectiveness of the Lilly Connected Care Program (LCCP) platform in glycemic control among patients with T2DM in China. Methods: This retrospective study included Chinese patients with T2DM (aged >= 18 years) from April 1, 2017, to January 31, 2020, for the LCCP group and from January 1, 2015, to January 31, 2020, for the non-LCCP group. Propensity score matching was used to match the LCCP and non-LCCP groups to reduce confounding, with covariates including age, sex, the duration of diabetes, baseline hemoglobin A(1c) (HbA(1c)), and the number of oral antidiabetic medication classes. HbA(1c) reduction over 4 months, the proportions of patients achieving an HbA(1c) reduction of >= 0.5% or >= 1%, and the proportions of patients reaching to target HbA1c level of <= 6.5% or <7% were compared between the LCCP and non-LCCP groups. Multivariate linear regression was used to assess factors associated with HbA(1c) reduction. Results: A total of 923 patients were included, among whom 303 pairs of patients were well matched after propensity score matching. HbA1c reduction during the 4-month follow-up was significantly larger in the LCCP group than the non-LCCP group (mean 2.21%, SD 2.37% vs mean 1.65%, SD 2.29%; P=.003). The LCCP group had a higher proportion of patients with an HbA(1c) reduction of >= 1% (209/303, 69% vs 174/303, 57.4%; P=.003) and >= 0.5% (229/303, 75.6% vs 206/303, 68%; P=.04). The proportions of patients reaching the target HbA1c level of =6.5% were significantly different between the LCCP and non-LCCP groups (88/303, 29% vs 61/303, 20.1%; P=.01), whereas the difference in the proportions of patients reaching the target HbA(1c) level of <7% was not statistically significant (LCCP vs non-LCCP: 128/303, 42.2% vs 109/303, 36%; P=.11). LCCP participation and higher baseline HbA(1c) were associated with a larger HbA(1c) reduction, whereas older age, longer diabetes duration, and higher baseline dose of premixed insulin analogue were associated with a smaller HbA(1c) reduction. Conclusions: The LCCP mobile platform was effective in glycemic control among patients with T2DM in China in the real world."

基金机构：Eli Lilly and Company

基金资助正文："The authors thank all the patients who participated in this study. The authors would also like to thank Happy Life Tech (HLT) , Yidu Tech Inc, for operation support. This study was funded by Eli Lilly and Company."